Novartis’ Jakavi bests current therapy for GvHD
REACH2 is the first Phase III study in steroid-refractory acute graft-versus-host-disease (GvHD) to have met its primary endpoint
Read More
Tag: ruxolitinib
Novartis, Incyte to test Jakavi for coronavirus-linked cytokine storm
Early clinical evidence suggests that the JAK inhibitor could reduce the number of patients requiring intensive care and mechanical ventilation
Read More
SMC green light for rare blood cancer treatment
NHS funding was backed for four medicines
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
